Illumina (NASDAQ:ILMN) Price Target Raised to $105.00

Illumina (NASDAQ:ILMN) had its price objective lifted by JPMorgan Chase & Co. from $100.00 to $105.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

Several other research firms have also commented on ILMN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Morgan Stanley upped their price target on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, August 4th. Evercore ISI upped their price target on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a research report on Friday, July 11th. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $115.00.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $123.64 on Friday. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The firm has a market cap of $19.00 billion, a price-to-earnings ratio of 15.65, a price-to-earnings-growth ratio of 2.34 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The business has a 50-day simple moving average of $98.41 and a two-hundred day simple moving average of $92.90.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The business’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts expect that Illumina will post 4.51 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rise Advisors LLC boosted its stake in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the period. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the period. Quent Capital LLC bought a new position in Illumina in the 3rd quarter worth approximately $29,000. Cullen Frost Bankers Inc. bought a new position in Illumina in the 2nd quarter worth approximately $41,000. Finally, NewSquare Capital LLC boosted its stake in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 369 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.